### Supplementary Table 1 – Medications and Clinical Outcomes During Follow-Up in Marfan and H-TAAD Groups

|                                      | Marfan       | H-TAAD gene unknown |
|--------------------------------------|--------------|----------------------|
| Nil Treatment                        | 127 (46%)    | 68 (47%)             |
| M / F                                | 60 / 67      | 48 / 20              |
| Age Start Follow-Up                  | 22.9 ± 16.6  | 47.8 ± 17.1          |
| Duration Follow-Up                   | 19.1 ± 11.7  | 10.4 ± 7.2           |
| Aortic Dissection                    | 20 (16%)     | 4 (6%)               |
| Type A                               | 9            | 3                    |
| Type B                               | 11           | 1                    |
| All Aortic Surgery                   | 49           | 30                   |
| Ascending Aorta                      | 38 (30%)     | 20 (29%)             |
| Death                                | 31 (24%)     | 8 (40%)              |
| Beta Blockers Only                   | 63 (23%)     | 24 (14%)             |
| M / F                                | 40 / 23      | 17 / 7               |
| Age Start Follow-Up                  | 19.0 ± 14.3  | 43.7 ± 16.4          |
| Duration Follow-Up                   | 22.1 ± 10.6  | 9.4 ± 7.5            |
| Aortic Dissection                    | 13 (21%)     | 0                    |
| Type A                               | 2            | 0                    |
| Type B                               | 11           | 0                    |
| All Aortic Surgery                   | 43           | 8                    |
| Ascending Aorta                      | 31 (49%)     | 7 (29%)              |
| Death                                | 10 (16%)     | 1 (4%)               |
| Angiotensin Blockers Only            | 31 (11%)     | 23 (16%)             |
|                  | Group 1 (22/9) | Group 2 (17/6) |
|------------------|----------------|----------------|
| M / F            | 22 / 9         | 17 / 6         |
| Age Start Follow-Up | 26.4 ± 20.8  | 50.7 ± 13.3   |
| Duration Follow-Up | 23.0 ± 13.3  | 8.7 ± 5.4     |
| Aortic Dissection | 4 (13%)        | 1 (4%)         |
| Type A           | 0              | 1              |
| Type B           | 4              | 0              |
| All Aortic Surgery | 16            | 5              |
| Ascending Aorta  | 11 (35%)       | 4 (17%)        |
| Death            | 8 (26%)        | 2 (8%)         |
| Combined Treatment | 57 (20%)     | 31 (21%)       |

|                  | Group 3 (40/17) | Group 4 (17/4) |
|------------------|-----------------|----------------|
| M / F            | 40 / 17         | 17 / 4         |
| Age Start Follow-Up | 20.3 ± 15.3   | 46.2 ± 17.9   |
| Duration Follow-Up | 20.3 ± 10.2  | 12.2 ± 10.9   |
| Aortic Dissection | 9 (16%)        | 3 (10%)        |
| Type A           | 3               | 0              |
| Type B           | 6               | 3              |
| All Aortic Surgery | 43             | 21             |
| Ascending Aorta  | 27 (47%)        | 11 (48%)       |
| Death            | 3 (5%) \(b\)   | 0              |

\(b p < 0.005 \) vs nil treatment.